Biotheranostics’ Chief Scientific Officer Nominated for Athena Pinnacle Award

Catherine Schnabel, Ph.D., Recognized for Supporting Women in the San
Diego Life Sciences Industry

SAN DIEGO–(BUSINESS WIRE)–Biotheranostics,
a leader in molecular diagnostics for cancer, today announced that
Catherine Schnabel, Ph.D., Chief Scientific Officer, has been nominated
for a 2016 Pinnacle Award by Athena, an organization dedicated to
promoting the professional growth of women executives and managers in
science and technology in San Diego.

Athena’s Pinnacle Awards recognize extraordinary women, men,
companies/organizations, and educators who personify Athena San Diego’s
mission of fostering the personal and professional growth of women
through mentoring, education, recognition, and leadership training,
thereby enhancing competitiveness and opportunity for women in the San
Diego business community.

“We are pleased that Cathy Schnabel has been recognized by Athena for
the significant role she plays in the development and advancement of
skilled and talented women within our organization and the San Diego
community,” said Nicolas Barthelemy, President and CEO of
Biotheranostics. “We are proud of the fact that Biotheranostics offers a
workplace where women can excel and thrive. About 80 percent of
Biotheranostics’ executive team are women, versus about half for our
overall employee population.”

Schnabel is an industry leader in the development of evidence-based
diagnostics and in building clinical value for molecular tests. Since
2009, she has led the translational science and strategic programs for
clinical development of Biotheranostics’ proprietary molecular
diagnostics in oncology and genomic medicine. Schnabel has more than 15
years of experience as an industry scientist across pharmaceutical,
clinical, and diagnostics research. She is a named co-inventor on
several patents and has authored numerous publications.

Athena Pinnacle Awards are presented in five categories, including Life
Sciences, Technology, Services, Education, and Company/Organization.
Nominees and winners will be celebrated at the 18th Annual Pinnacle
Awards dinner and auction April 28, 2016, at the Manchester Grand Hyatt
in downtown San Diego.

About Biotheranostics
Biotheranostics,
Inc
., is a leader in helping physicians improve the care of cancer
patients, offering a suite of proprietary molecular diagnostic tests
that allow treatment to be tailored to individual patients. The
company’s CancerTYPE
ID®
is the most rigorously validated gene expression test
for metastatic patients with diagnostic ambiguity, helping physicians
determine optimal site-directed treatment regimens with the goal of
improving patient outcomes. Its Breast
Cancer IndexSM
helps oncologists make difficult decisions
about extended endocrine therapy for ER+ breast cancer patients based on
its unique ability to predict risk of late disease recurrence and
identify which patients are likely to benefit from continuing therapy
beyond five years. Biotheranostics is based in San Diego. For more
information, visit www.biotheranostics.com.

Contacts

Sullivan & Associates
Barbara Sullivan, 714-374–6174
bsullivan@sullivanpr.com